Year All 2026 2025 2024 2023 2022 2021 2020 2019 Nov 04, 2026 Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile Oct 20, 2026 Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026 Oct 12, 2026 Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth Oct 01, 2026 Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days Sep 22, 2026 Harmony Biosciences Recognizes World Narcolepsy Day 2026, Reflecting on Nearly a Decade of Commitment to the Sleep Community Sep 03, 2026 Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress Aug 27, 2026 Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference Aug 06, 2026 Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium Aug 04, 2026 Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile Jul 21, 2026 Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
Nov 04, 2026 Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
Sep 22, 2026 Harmony Biosciences Recognizes World Narcolepsy Day 2026, Reflecting on Nearly a Decade of Commitment to the Sleep Community
Sep 03, 2026 Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
Aug 04, 2026 Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
